Understanding PDE4D Mutations and Their Implications in Disease

Target Name: PDE4D

NCBI ID: G5144

PDE4D

Understanding PDE4D Mutations and Their Implications in Disease

The protein encoded by the gene PDE4D (4D kinase) is a key regulator of cell signaling pathways, including the G-protein-coupled receptor (GPCR) signaling pathway. Mutations in the PDE4D gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Despite the growing interest in this gene, the function and significance of PDE4D mutations in human disease remain poorly understood.

In this article, we will focus on the PDE4D gene and its role in disease, as well as the potential implications of targeting this gene as a drug target or biomarker.

PDE4D gene and protein

The PDE4D gene is located on chromosome 12q34 and encodes a 21-kDa protein. The protein encoded by PDE4D consists of a catalytic alpha-helices, a transmembrane segment, and a cytoplasmic tail. The alpha-helices are responsible for the protein's catalytic activity, while the transmembrane segment houses the protein's regulatory interactions and the cytoplasmic tail is involved in protein stability and localization.

PDE4D functions as a negative regulator of the GPCR signaling pathway

The GPCR signaling pathway is a critical pathway involved in many physiological processes, including sensory perception, neurotransmission, and hormone signaling. The PDE4D protein plays a crucial role in regulating the activity of GPCRs by activating the cAMP-protein kinase (PKA) and inhibiting the catalytic activity of the protein Pyknotide.

Activation of PKA by PDE4D occurs through a G-protein-coupled receptor (GPCR) kinetic switch, in which the GPCR is phosphorylated and the Pyknotide protein is recruited to the receptor, leading to the formation of a cAMP-phospho-Pyknotide complex. The formation of this complex facilitates the transfer of the phosphate group from Pyknotide to the GPCR, resulting in the activation of the PKA and the subsequent increase in cAMP concentration.

In contrast, inhibition of Pyknotide by PDE4D occurs through a GPCR-Pyknotide interaction, in which the Pyknotide protein is phosphorylated by the GPCR, leading to the formation of a Pyknotide-phosphorylated-GPCR (PPG) complex. The formation of this complex inhibits the activity of Pyknotide and reduces the concentration of cAMP.

The PDE4D gene is mutated in many diseases

Mutations in the PDE4D gene have been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The most well-studied PDE4D mutations are missense mutations, which occur in the catalytic alpha-helices and transmembrane segments of the protein.

Mutations in the catalytic alpha-helices of PDE4D have been linked to various diseases, including cancer. For example, missense mutations in the alpha-helix region of the PDE4D gene have been implicated in the development of breast cancer. Similarly, mutations in the transmembrane segment of PDE4D have been associated with neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Targeting PDE4D as a drug target or biomarker

The PDE4D gene has been targeted as a potential drug target due to its involvement in the GPCR signaling pathway and its role in the development of various diseases. One approach to targeting PDE4D is to inhibit its catalytic activity

Protein Name: Phosphodiesterase 4D

Functions: Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes

The "PDE4D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDE4D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets